AKYLA/ Financials
MarketsScreenerFinancialsResearchChat
Equity / BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Fennec Pharmaceuticals Inc. Common Stock
XNAS · usd
SIC 2836 · BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
FIGI BBG001S69M23
10.08▼ 0.24 (-2.33%)
As of 2026-10-23
Price / Volume
Valuation
Market Cap
Enterprise Value
—
Trailing P/E
—
Price / Sales
EV / Revenue
—
EV / EBITDA
—
Financial Highlights
Revenue (TTM)
Net Income (TTM)
EBITDA
—
Diluted EPS (TTM)
EBITDA Margin
—
Net Debt
—
Trading Information
Previous Close
10.32
Day's Range
9.93 – 10.48
52-Week Range
5.51 – 13.25
Volume
70.8K
Avg Volume
130.0K
Share Statistics
Shares Outstanding
Employees
35
Exchange
XNAS
Listed
2002-01-28
Share count as of August 11, 2026

Fennec Pharmaceuticals Inc. Common Stock (FENC) Financial Statements

View
Income Statement
Detail
Standard
Period
Quarterly
Loading Income Statement…
Key questions about Fennec Pharmaceuticals Inc. Common Stock (FENC)
What is Fennec Pharmaceuticals Inc. Common Stock's Market Cap?
Fennec Pharmaceuticals Inc. Common Stock's Market Cap is $353.5M, based on as-reported figures from SEC (XBRL) filings.
What is Fennec Pharmaceuticals Inc. Common Stock's Price / Sales?
Fennec Pharmaceuticals Inc. Common Stock's Price / Sales is 6.0×, based on as-reported figures from SEC (XBRL) filings.
What is Fennec Pharmaceuticals Inc. Common Stock's Revenue (TTM)?
Fennec Pharmaceuticals Inc. Common Stock's Revenue (TTM) is $59.2M, based on as-reported figures from SEC (XBRL) filings.
What is Fennec Pharmaceuticals Inc. Common Stock's Net Income (TTM)?
Fennec Pharmaceuticals Inc. Common Stock's Net Income (TTM) is -$3.3M, based on as-reported figures from SEC (XBRL) filings.
What is Fennec Pharmaceuticals Inc. Common Stock's Diluted EPS (TTM)?
Fennec Pharmaceuticals Inc. Common Stock's Diluted EPS (TTM) is -0.09, based on as-reported figures from SEC (XBRL) filings.
Akyla / Financials · FENCAs-filed SEC (XBRL) data
Showing the most recent year. Subscribe for full statement history.
Income Statement(in thousands of USD, except per-share data)
Source: Akyla.ai
Line ItemJun 30, 2026Mar 31, 2026Dec 31, 2025Sep 30, 2025Jun 30, 2025Mar 31, 2025Dec 31, 2024Sep 30, 2024Jun 30, 2024Mar 31, 2024Dec 31, 2023Sep 30, 2023Jun 30, 2023Mar 31, 2023Dec 31, 2022Sep 30, 2022
Condensed Consolidated Statements of Operations
Total revenue
YoY growth+85.2%+72.6%+73.8%+78.7%
Operating expenses:
Cost of product sales
Research and development
Selling and marketing
General and administrative
Total operating expenses
% of revenue-90.3%100.8%620.7%-101.5%
Income/(loss) from operations
% of revenue9.7%-0.8%-18.5%-1.5%
Other income/(expense)
Unrealized foreign exchange (loss)/gain
Amortization expense——
Unrealized loss on securities——
Interest income
Interest expense
Total other income/(expense)
Income/(loss) before provision for income taxes———
Provision for income taxes———
Net income/(loss)
% of revenue11.0%1.3%-34.7%-5.1%
Basic net income/(loss) per common share
Diluted net income/(loss) per common share